Zura Bio Limited (NASDAQ:ZURA) Director Parvinder Thiara Sells 1,001,633 Shares

Zura Bio Limited (NASDAQ:ZURA) Director Parvinder Thiara sold 1,001,633 shares of the stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $2.73, for a total value of $2,734,458.09. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Zura Bio Stock Down 0.3 %

ZURA traded down $0.01 on Wednesday, hitting $3.00. 228,283 shares of the company’s stock traded hands, compared to its average volume of 327,384. The company’s 50 day simple moving average is $4.12 and its 200-day simple moving average is $4.03. Zura Bio Limited has a one year low of $2.00 and a one year high of $6.35.

Zura Bio (NASDAQ:ZURA) last announced its earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Research analysts expect that Zura Bio Limited will post -0.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zura Bio

Several hedge funds have recently made changes to their positions in the company. Braidwell LP bought a new position in shares of Zura Bio in the 3rd quarter worth $10,040,000. Point72 Asset Management L.P. acquired a new position in Zura Bio during the 2nd quarter valued at about $8,446,000. Great Point Partners LLC increased its position in Zura Bio by 68.3% during the 2nd quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock valued at $16,248,000 after buying an additional 1,884,501 shares in the last quarter. Armistice Capital LLC increased its holdings in shares of Zura Bio by 53.2% in the second quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after purchasing an additional 876,000 shares during the period. Finally, Sphera Funds Management LTD. acquired a new position in shares of Zura Bio in the third quarter valued at about $2,999,000. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ZURA. Piper Sandler reiterated an “overweight” rating and issued a $26.00 price objective on shares of Zura Bio in a report on Thursday, September 19th. Leerink Partnrs upgraded Zura Bio to a “strong-buy” rating in a report on Monday, November 4th. Chardan Capital dropped their price objective on Zura Bio from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, November 8th. HC Wainwright reaffirmed a “neutral” rating and set a $5.00 price objective on shares of Zura Bio in a research report on Monday, November 18th. Finally, Leerink Partners started coverage on Zura Bio in a research report on Monday, November 4th. They set an “outperform” rating and a $15.00 price objective on the stock. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $15.80.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.